close

Enter

Log in using OpenID

Hepatic Encephalopathy Market

embed
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to witness a CAGR of 6.3% during 2018 – 2026.
Hepatic Encephalopathy Market Size, Share,
Trend, Outlook, Future Growth Analysis
And Synthesis 2018 - 2026
Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the liver
disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of ammonia,
which can cross the blood–brain barrier and cause significant neurocognitive impairment. A significant
number of patients with cirrhosis may experience HE and may be at high risk of recurrent HE.
The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert Hepatic
Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated with high rates of
mortality and hospitalizations and poor quality of life. Factors such as infections, gastrointestinal
bleeding, metabolic disturbance, and dietary protein overload may cause OHE. According to a study
conducted by the U.S. National Library of Medicine in 2016, 30 to 50% of patients who have cirrhosis
during their clinical care are likely to develop OHE.
Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2596
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is expected to
witness a CAGR of 6.3% during the forecast period (2018 – 2026).
Increasing number of drugs in pipeline for the treatment of HE is expected to drive the market growth
during the forecast period
There are different types of therapeutic drugs in pipeline for the treatment of HE. Increasing number of
products in pipeline for the treatment of HE is expected to drive growth of the market over the forecast
period.
Umecrine Cognition, a Sweden-based pharmaceutical company, is developing a therapy that represents a
new target class for several major central nervous system (CNS)-related disorders. The lead compound
GR3027 is presently in clinical development for HE. The company plans to demonstrate Phase II data of
GR3027 for the treatment of HE in 2020.
Increasing prevalence of various types of liver diseases is expected to aid in the market growth
HE is a sign of poor prognosis and correlates with mortality in both patients with acute liver failure and
those with cirrhosis associated with end stage liver disease. Liver cirrhosis is a gastroenterological
condition that is characterized by a slow, progressive, and irreversible replacement of liver cells by
fibrous tissue (scar) that prevents normal liver functioning.
According to the National Center for Biotechnology Information (NCBI): 2014, generally liver cirrhosis
affects up to 1% of the U.S. and EU population. Between 180,000 and 290,000 patients with cirrhosis in
the U.S. are hospitalized due to complications of HE. Once HE develops, mortality reaches 22-35% after
five years. HE is also associated with increased hospitalization and treatment costs. Moreover, subtle
signs of HE are observed in around 70% of patients with cirrhosis.
Report includes chapters which deeply display the following deliverable about industry :
• Hepatic Encephalopathy Market Research Objective and Assumption
• Hepatic Encephalopathy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Hepatic Encephalopathy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Hepatic Encephalopathy Market, By Regions
• Hepatic Encephalopathy Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Hepatic Encephalopathy Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Hepatic Encephalopathy Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Hepatic Encephalopathy Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key Players
Key players operating in the global hepatic encephalopathy market include, ASKA Pharmaceutical Co.,
Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch
Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition
AB, and Norgine B.V.
Detailed Segmentation:
Global Hepatic Encephalopathy Market, By Drug Class:
•
Antibiotic
•
Laxatives
•
Others
Global Hepatic Encephalopathy Market, By Distribution Channel:
•
Hospital Pharmacies
•
Retail Pharmacies
•
Online Pharmacies
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/
hepatic-encephalopathy-market-2596
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master247   documents Email
Document
Category
Health and Medicine
Views
3
File Size
120 KB
Tags
market, Hepatic Encephalopathy Market
1/--pages
Report inappropriate content